Discoverybiomed Inc., of St. Louis, was awarded a $1.61 million phase 2 Small Business Innovation Research grant award from the National Institutes of Health and its National Institute of Diabetes, Digestive and Kidney Diseases to develop first-in-class small-molecule drugs to fight multiple disease abnormalities caused by high blood sugar (hyperglycemia) and high blood fat such as metabolic syndrome, type 2 diabetes mellitus and obesity.